Incretin therapy and islet pathology: a time for caution.
about
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and MassSafety of dipeptidyl peptidase 4 inhibitors: a perspective reviewAction and therapeutic potential of oxyntomodulinSafety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitusPathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future.Human β-cell regeneration: progress, hurdles, and controversy.Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety.The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.Extra-pancreatic effects of incretin-based therapies.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.An updated review on cancer risk associated with incretin mimetics and enhancers.Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.Pancreas Volume and Fat Deposition in Diabetes and Normal Physiology: Consideration of the Interplay Between Endocrine and Exocrine PancreasEffects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys.Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.Incretin-based therapies: facing the realities of benefits versus side effects.The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.Association between dipeptidyl peptidase-4 inhibitor drugs and risk of acute pancreatitis: A meta-analysis.Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.Pancreatic safety of GLP-1-based therapeutic agents: further insights from rodent studies?Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice.Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
P2860
Q26749089-7A7F13FE-0CDF-4F02-8446-6A4C813016D3Q26863262-6150CB32-07C0-4921-BB2D-5A3AFE329AFAQ27025870-A2CC3373-E4C8-40F1-9510-21D5A0E25194Q27027877-D50CB123-19C6-43A0-A257-8D413D76A72DQ30597265-D1871977-3277-473B-A198-9429E0705990Q33776142-740C1571-8174-4983-ACB2-6464F3B0D387Q34490448-0B25F108-1207-41AA-BA66-BB8B418700FFQ34547492-657F345F-F1DB-429C-A011-A97A2FFC8FCAQ37195882-7EBAD03E-77C4-4119-9C0B-6FD1A2B17B29Q37476451-36D99191-32D5-4FC2-AC9F-A71D3036AAE2Q38126945-619CE1D8-FF0F-4573-92EA-800B214965A9Q38145277-4EDF6F08-3783-4842-A42C-5B1011AA8121Q38174279-98363C9E-92BF-4565-87F4-FE223A0BB0C3Q38194069-F508C3E7-3BFE-47DE-8AE1-274641227B21Q38286444-8BF4DF0F-9BB1-4715-8F13-FA8698BAB9D3Q38388920-99BF6138-3C36-4E56-BCD7-766801449B2BQ38601929-A22EC899-781C-464F-B0F5-755DB147480AQ39017198-CC776EA3-9EF6-499C-A12B-8659728396C3Q39052404-9C550346-100E-46B6-B016-A5F7CABE0DF2Q40852125-12DDEC56-8846-4E93-B4A0-1D228CD2865AQ42874262-787D51D9-639A-4AE1-8BE5-D902EDB5E4E0Q42921290-D7308F6F-99A8-4F04-AFD4-65AAC4933DD9Q45778975-2EAF5FB9-14E6-4F84-91DE-6792A9A377B5Q47096196-4F9B03BE-68DA-4A9A-AA07-14E8122D0572Q47196605-99F208CC-718E-4AF6-A41D-1C9F8D4ED2DCQ48007843-DDDDFD7A-D65E-4578-BC39-974E3FEE0F22Q50862636-829E057A-7B5A-4C77-889B-2BB956D916FCQ52741508-5D1D8058-0E11-475E-9C04-235073D292B0Q54420490-C421A1E5-CFD5-4D5A-8F3B-1EB4ECE3941A
P2860
Incretin therapy and islet pathology: a time for caution.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Incretin therapy and islet pathology: a time for caution.
@en
Incretin therapy and islet pathology: a time for caution.
@nl
type
label
Incretin therapy and islet pathology: a time for caution.
@en
Incretin therapy and islet pathology: a time for caution.
@nl
prefLabel
Incretin therapy and islet pathology: a time for caution.
@en
Incretin therapy and islet pathology: a time for caution.
@nl
P2860
P356
P1433
P1476
Incretin therapy and islet pathology: a time for caution.
@en
P2860
P304
P356
10.2337/DB13-0520
P407
P577
2013-04-17T00:00:00Z